Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesMultipotent mesenchymal stromal cells and rheumatoid arthritis: Risk or benefit?
Rheumatology, 07/01/09
Bouffi C et al. – Review discusses the new potential therapeutic applications of mesenchymal stromal cells (MSC)-based therapy in osteo-articular diseases, and also assesses the potential risks associated with it.
- MSCs play a dual role that may be of benefit in RA owing to their immunosuppressive properties and their potential of differentiation towards chondrocytes
- MSC-based cartilage engineering is a promising approach in case of cartilage injury
- It must be underlined that in case of chronic inflammation, the differentiation ability of MSCs is inhibited
- MSCs exert their immunosuppressive effect after activation by pro-inflammatory cytokines such as IFN-γ and IL-1β, secreted in arthritic joints
- Indeed, the local inflammation may be important for MSCs to display their therapeutic efficacy in RA
- An in vitro step of pre-conditioning of MSCs may also be required to more efficiently trigger the immunomodulatory potential of MSCs
- In conclusion, stromal cells appear as major regulatory cells in skeletal tissue homeostasis, controlling inflammation, immune response, fibrosis and tissue regeneration
Related Articles
Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09
Relevance Score: 71%
Certolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/11/09
Relevance Score: 70%
Assistive technology for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 70%
Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/06/09
Relevance Score: 69%
Abatacept for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 69%
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Identification of Cutpoints for Acceptable Health Status and Important Improvement in Patient-Reported Outcomes, in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Journal of Rheumatology, 12/08/09
TNF{alpha} blockade therapy reduces circulating NT-proBNP levels in RA patients with active disease: Results from prospective cohort study
Annals of Rheumatic Diseases, 12/07/09
Sponsor
Article Search
Sponsor